AnaptysBio, a clinical-stage biotechnology company developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, has appointed Matthew Moyle as Chief Scientific Officer. Dr Moyle will be responsible for the discovery and early development of therapeutic antibodies generated using the San Diego, US-based firm's proprietary SHM-XEL platform.
Dr Moyle joins AnaptysBio with more than 25 years of industry experience in discovery and development of biologic therapeutics. Most recently, he was Vice President of Biotherapeutics at Boehringer Ingelheim Pharmaceuticals, where he chaired Boehringer Ingelheim's International NBE Council.
Prior to that, he was Senior Vice President R&D and CSO of Theraclone Sciences, and Vice President Research of Tanox, where he led the design and development of monoclonal antibody therapeutic candidates, several of which are currently undergoing clinical development at Roche, Novartis and Gilead.
Before Tanox, he served in various positions at Amgen, Corvas and Genentech.
